AIxCrypto Holdings Signs Non‑Binding LOI with Faraday Future Robotics to Explore On‑Chain DePIN Integration
- AIxCrypto announced a non‑binding LOI with Faraday Future’s FF EAI‑Robotics to explore collaboration. • The LOI is exploratory, assessing Web3 technical alignment and potential integration of robotics into AIxCrypto’s blockchain. • AIxCrypto will evaluate robotics as DePIN gateways, EAI Brain for on‑chain compute, and EAI data to improve AI agents.
Los Angeles weekly update
AIxCrypto Holdings issues a business update from Co‑CEO Jerry Wang in Los Angeles, outlining a non‑binding letter of intent with FF EAI‑Robotics, the robotics arm of Faraday Future. The announcement frames the engagement as an evaluation of Web3 collaboration and strategic technical alignment rather than a binding commercial deal, and it signals a potential move to integrate physical robotics into AIxCrypto’s blockchain infrastructure.
Evaluating robotics as on‑chain gateways
Under the letter of intent, AIxCrypto and FF EAI‑Robotics are assessing three strategic synergies that could reframe how physical devices interact with on‑chain systems. First, they explore user‑owned robotics functioning as DePIN (decentralized physical infrastructure network) endpoints that act as physical‑world gateways into the AIxC ecosystem, enabling devices to serve as points where real‑world actions and assets are recorded and monetized on chain.
Second, the parties consider leveraging the EAI Brain and an open‑source, open‑platform approach to create a stronger on‑chain execution and data availability layer. AIxCrypto views this as a potential attractor for developers and a mechanism to build a high‑quality, engaged Web3 user base by simplifying on‑chain computation and access to multimodal data streams from robotics.
Third, Faraday Future’s EAI Decentralized Data Factory is under review as a source of high‑quality, multimodal real‑world behavioral data. AIxCrypto is evaluating how such data could feed machine learning pipelines, improve agent performance like its BesTrade DeAI Agent, and help bridge physical‑world telemetry with tokenized value and incentive systems on chain.
Non‑binding terms and evaluation focus
The companies stress that the LOI is non‑binding and that any collaboration will be subjected to technical, commercial and governance assessments. Key evaluation items include models for data sharing, DePIN incentive design, developer onboarding strategies, regulatory and securities compliance, and mechanisms to align stakeholder value while protecting user privacy and data integrity.
Other corporate context
AIxCrypto reiterates its mission as a U.S. Nasdaq‑listed company building an ecosystem that integrates AI and blockchain to bridge Web2 and Web3, with core products including the BesTrade DeAI Agent and other AIxC ecosystem offerings. The update emphasizes long‑term execution on product development, operational strengthening, disciplined capital management and transparent shareholder communication, while noting customary forward‑looking statement cautions.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…